Phase 3, Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Lenalidomide Not-Refractory, 1,2,3 prior line of therapy
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 3, Proteasome Inhibitors (PI), Dexamethasone+Lenalidomide+Carfilzomib (KRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Lenalidomide Not-Refractory, 1,2,3 prior line of therapy 
### Output:
Popular Name is ASPIRE, Study ID is NCT01080391